HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:
Sign In to gain access to subscriptions and/or personal tools.

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in Web of Science Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Request Reprints Citing Articles Citing Articles via HighWire Citing Articles via Web of Science (1) Citing Articles via Google Scholar Google Scholar Articles by Lehmann, D. Articles by Smith, A. Search for Related Content PubMed PubMed Citation Articles by Lehmann, D. Articles by Smith, A. Social Bookmarking                         What's this?

Lack of Attenuation in the Antitumor Effect of Tamoxifen by Chronic CYP Isoform Inhibition

From SUNY Upstate Medical University, Syracuse, New York.

Tamoxifen is a selective estrogen receptor modulator used in estrogen receptor-positive breast cancer. Tamoxifen is metabolized to an extremely potent antiestrogen by cytochrome P450 (CYP) 2D6, 2C9, and 3A isoforms. The selective serotonin reuptake inhibitors (SSRIs) are potent inhibitors of these CYPs. Since the prevalence of depression in breast cancer patients is nearly triple that of the general population, it is likely that a subgroup of breast cancer patients will receive long-term treatment with both an SSRI and tamoxifen. A case control design was used to investigate the possibility that a resultant decrease in production of the 4-hydroxy metabolite from chronic inhibition results in the attenuation of the antitumor effect of tamoxifen. Twenty-eight patients without recurrences of breast cancer (controls) were matched to an equal number of cases (recurrences) by cancer stage and year of diagnosis. Data were analyzed on all chronic medication exposure (> 3 months) in both cases and controls classified as to their status as CYP 2D6, 2C9, and 3A inhibitors, substrates, or inducers. No significant difference was found for CYP inhibitor or substrate exposure between cases and controls. Indeed, controls showed a slightly greater exposure to inhibitors of the relevant CYP isoforms compared to cases. These results suggested a trend toward the null hypothesis. It is unlikely that the effect of chronic exposure to potent CYP isoform inhibitors affects the antitumor effect of tamoxifen and its 4-hydroxy metabolite, supporting the safety of the continued practice of concomitant SSRI administration to breast cancer patients with depression.

Key Words: Selective serotonin reuptake inhibitors • tamoxifen • estrogen receptor-positive breast cancer • depression • CYP isoform inhibition

Address for reprints: David Lehmann, MD, 750 Adams Street, Syracuse, NY 13210.

CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				T. L. Lash and C. L. Rosenberg Evidence and Practice Regarding the Role for CYP2D6 Inhibition in Decisions About Tamoxifen Therapy J. Clin. Oncol., March 10, 2010; 28(8): 1273 - 1275. [Full Text] [PDF]

				C. M Kelly, D. N Juurlink, T. Gomes, M. Duong-Hua, K. I Pritchard, P. C Austin, and L. F Paszat Selective serotonin reuptake inhibitors and breast cancer mortality in women receiving tamoxifen: a population based cohort study BMJ, February 8, 2010; 340(feb08_1): c693 - c693. [Abstract] [Full Text] [PDF]

				F. Andersohn and S. N Willich Interaction of serotonin reuptake inhibitors with tamoxifen BMJ, February 8, 2010; 340(feb08_3): c783 - c783. [Full Text]